Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Fixed-sequence Study of Effect of Gefitinib on the Pharmacokinetics of Apatinib Mesylate in Non-squamous, Non-small-cell Lung Cancer Patients

Next Previous
Trial Profile

A Multi-center, Open-label, Fixed-sequence Study of Effect of Gefitinib on the Pharmacokinetics of Apatinib Mesylate in Non-squamous, Non-small-cell Lung Cancer Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary) ; Gefitinib
  • Indications Lung cancer; Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 07 Jan 2021 Planned number of patients changed from 18 to 22.
  • 07 Jan 2021 Planned End Date changed from 1 Aug 2020 to 1 Mar 2021.
  • 07 Jan 2021 Planned primary completion date changed from 1 Jul 2020 to 1 Feb 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top